The Opportunity

  • ABV100 platform will become a replacement for rapid acting insulin that can be used anywhere and with any patient type (T1D, T2D, Injections, pumps)

  • Protects against hypoglycemia allowing safer use of insulin and better control of diabetes that in turn allows much improved long term health

  • Pharmacological platform leverages two well known FDA-approved peptides (many decades of use in humans)

  • Human proof of concept already achieved with prototype co-formulations

  • De-risked and streamlined path to market
  • Non-dilutive funding, strong IP position


  • Proof of concept in a large animal model
  • Human POC study using a co-infusion has validated the approach
  • Candidate formulations demonstrate feasibility of a stable combination product
  • Strong IP Portfolio
  • Non-dilutive funding to date

Learn More

    Abvance Therapeutics does not sell, rent or provide your email to any third party.